YM Biosciences Share Price - YM, RNS News, Articles, Share Price Quotes, Charts, & Stock Market information( AMEX:YMI, )

YM Biosciences
www.ymbiosciences.com

YM BioSciences is engaged in the licensing and commercialization of drug products and technologies from original research.

The Company is advancing two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer, and AeroLEF, an inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain.

Its products in clinical development target solid tumors, including colorectal, prostate, head and neck, breast, pancreatic, esophageal, specific types of brain tumors and acute pain, including cancer pain.

News

All YM Biosciences News ►

Recent Sector News

Dow seen opening higher ahead of jobless data, Facebook, Hewlett-Packard in focus

U.S. equity markets looked set to point to open higher Thursday after strong earnings from Hewlett-Packard (NYSE:HPQ), and as talks progress on Greece's debt crisis.
Q1 gold demand underpinned by China, Central Banks and ETFs

Global gold demand in the first quarter of 2012 was 1,097.6 tonnes, down 5 percent from the high demand levels seen a year earlier, according to the World Gold Council.
Medgenics cleared by FDA to begin Phase IIb clinical trials for EPODURE; shares up

Biopharmaceutical company Medgenics (LON:MEDG, AMEX:MDGN) achieved a major milestone today - with clearance to begin a phase IIb trial of EPODURE to treat anaemia in kidney failure patients.
Facebook boosts public offering by 25%

Social network site Facebook Wednesday increased the size of its initial public offering by almost 25 per cent as it could raise as much as $16 billion on strong investor demand for its market debut.
Snipp plans ambitious growth as mobile marketing takes off

Mobile marketing company Snipp (CVE:SPN) (TSX.V:SPN), which recently listed on the TSX Venture Exchange, is now seeking a listing on the OTC exchange as it continues to grow in a space that is seeing more and more traction from companies looking to boost their marketing efforts.
Facebook ups IPO price range

Facebook has increased the price range in Silicon Valley's biggest-ever initial public offering to raise more than $12 billion, giving the social network a valuation potentially exceeding $100 billion.